
    
      A total of 82 subjects with relapsed or refractory multiple myeloma (RRMM) who have received
      at least 2 prior lines of treatment will be enrolled in this study. Prior lines of treatment
      must include a proteasome inhibitor (PI) and an immunomodulator (IMiD). All subjects will
      receive TJ202 and dexamethasone (DEX) in the study. The treatment will continue until
      endpoint events such as intolerance or progressive disease (PD).
    
  